Biotech News
Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
Real-Time Variant Tracker™ supplemental results track resistance and therapeutically targetable variants as cancer biology evolves. FREMONT, Calif. --(BUSINESS WIRE)--Oct. 20, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of
